The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: Initial results of the protein kinase C β inhibitor diabetic retinopathy study (PKC-DRS) multicenter randomized clinical trial

Diabetes

Volumn 54, Issue 7, 2005, Pages 2188-2197

  Aiello, Lloyd Paul ^a  

^a JOSLIN DIABETES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; NITRATE; PROTEIN KINASE C BETA; PROTEIN KINASE C INHIBITOR; RUBOXISTAURIN;

ADULT; ARTHRALGIA; ARTICLE; ASTHMA; ATRIOVENTRICULAR BLOCK; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC RETINOPATHY; DIARRHEA; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DYSURIA; FACIAL NERVE PARALYSIS; FEMALE; FLATULENCE; HEMOPTYSIS; HUMAN; HYPERKERATOSIS; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MUSCLE WEAKNESS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEINURIA; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RETINOPATHY; STOMACH CANCER; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT;

ADULT; AGED; AGED, 80 AND OVER; DIABETIC RETINOPATHY; DISEASE PROGRESSION; ENZYME INHIBITORS; FEMALE; HUMANS; INDOLES; MALE; MALEIMIDES; MIDDLE AGED; PATIENT SELECTION; PLACEBOS; PROTEIN KINASE C; TREATMENT OUTCOME; VISION DISORDERS;

EID: 21344435254     PISSN: 00121797     EISSN: None     Source Type: Journal    
DOI: 10.2337/diabetes.54.7.2188     Document Type: Article

References (46)

1. Wild S, Roglic G, Green A, Sicree R, King H: Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
2. Kempen JH, O'Colmain BJ, Leske MC, Haffher SM, Klein R, Moss SE, Taylor HR, Hamman RP: The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 122:552-563, 2004
3. Klein R, Klein BE, Moss SE: The Wisconsin Epidemiological Study of Diabetic Retinopathy: a review. Diabetes Metab Rev 5:559-570, 1989
4. Blindness caused by diabetes: Massachusetts, 1987-1994. MMWR Morb Mortal Wkly Rep 45:937-941, 1996
5. Early photocoagulation for diabetic retinopathy: ETDRS report number 9: Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 98:766-785, 1991
6. The Diabetes Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986, 1993
7. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
8. Sheetz MJ, King GL: Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288:2579-2588, 2002
9. Mellor H, Parker PJ: The extended protein kinase C superfamily. Biochem J 332:281-292, 1998
10. Bullock WH, Magnuson SR, Choi S, Gunn DE, Rudolph J: Prospects for kinase activity modulators in the treatment of diabetes and diabetic complications. Curr Top Med Chem 2:915-938, 2002
11. Aiello LP, Bursell S-E, Clermont A, Duh E, Ishii H, Takagi C, Mori F, Ciulla TA, Ways K, Jirousek M, Smith LEH, King GL: Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46:1473-1480, 1997
12. Xu X, Zhu Q, Xia X, Zhang S, Gu Q, Luo D: Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 28:251-256, 2004
13. Danis RP, Bingaman DP, Jirousek M, Yang Y: Inhibition of intraocular neovascularization caused by retinal ischemia in pigs by PKC β inhibition with LY333531. Invest Ophthalmol Vis Sci 39:171-179, 1998
14. Aiello LP, Bursell SE, Devries T, Alatorre C, King GL, Ways DK: Amelioration of abnormal retinal hemodynamics by a protein kinase C β selective inhibitor (LY333531) in patients with diabetes: results of a phase 1 safety & pharmacodynamic clinical trial. Invest Ophthalmol Vis Sci 40:8192, 1999
15. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S: Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 133:537-543, 2002
16. Suzuma K, Takahara N, Suzuma I, Isshiki K, Ueki K, Leitges M, Aiello LP, King GL: Characterization of protein kinase C β isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization. Proc Natl Acad Sci U S A 99:721-726, 2002
17. Koya D, Haneda M, Nakagawa H, Isshiki K, Sato H, Maeda S, Sugimoto T, Yasuda H, Kashiwagi A, Ways DK, King GL, Kikkawa R: Amelioration of accelerated diabetic mesangial expansion by treatment with a PKC β inhibitor in diabetic db/db mice, a rodent model for type 2 diabetes. FASEB J 14:439-447, 2000
18. Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A, Bursell SE, Kern TS, Ballas LM, Heath WF, Stramm LE, Feener EP, King GL: Amelioration of vascular dysfunctions in diabetic rats by an oral PKC β inhibitor. Science 272:728-731, 1996
19. Cotter MA, Jack AM, Cameron NE: Effects of the protein kinase C β inhibitor LY333531 on neural and vascular function in rats with streptozotocin-induced diabetes. Clin Sci (Lond) 103:311-321, 2002
20. Kelly DJ, Zhang Y, Hepper C, Gow RM, Jaworski K, Kemp BE, Wilkinson-Berka JL, Gilbert RE: Protein kinase Cβ inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52:512-518, 2003
21. Early Treatment Diabetic Retinopathy Study Research Group: Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics: ETDRS report number 7. Ophthalmology 98:741-756, 1991
22. Early Treatment Diabetic Retinopathy Study Group: Early Treatment Diabetic Retinopathy Study (ETDRS) Manual of Operations. Springfield, Virginia, U.S. Department of Commerce, National Technical Information Service, 1993
23. Early Treatment Diabetic Retinopathy Study Research Group: Grading diabetic retinopathy from stereoscopic color fundus photographs: an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology 98:786-806, 1991
24. Early Treatment Diabetic Retinopathy Study Research Group: Fundus photographic risk factors for progression of diabetic retinopathy: ETDRS report number 12. Ophthalmology 98:823-833, 1991
25. The Diabetes Control and Complications Trial Research Group: Clustering of long-term complications in families with diabetes in the Diabetes Control and Complications Trial. Diabetes 46:1829-1839, 1997
26. demons TE, Chew EY, Bressler SB, McBee W: National Eye Institute Visual Function Questionnaire in the Age-Related Eye Disease Study (AREDS): AREDS report no. 10. Arch Ophthalmol 121:211-217, 2003
27. Idris I, Gray S, Donnelly R: Protein kinase C β inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro. Eur J Pharmacol 485:141-144, 2004
28. Xia P, Aiello LP, Ishii H, Jiang ZY, Park DJ, Robinson GS, Takagi H, Newsome WP, Jirousek MR, King GL: Characterization of vascular endothelial growth factor's effect on the activation of protein kinase C, its isoforms, and endothelial cell growth. J Clin Invest 98:2018-2026, 1996
29. Xia P, Inoguchi T, Kern TS, Engerman RL, Gates PJ, King GL: Characterization of the mechanism for the chrome activation of diacylglycerol-protein kinase C pathway in diabetes and hypergalactosemia. Diabetes 43:1122-1129, 1994
30. Shiba T, Inoguchi T, Sportsman JR, Heath WF, Bursell S, King GL: Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am J Physiol 265:E783-E793, 1993
31. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480-1487, 1994
32. Ozaki H, Seo MS, Ozaki K, Yamada H, Yamada E, Okamoto N, Hofmann F, Wood JM, Campochiaro PA: Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 156:697-707, 2000
33. Aiello LP, Wong JS: Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int Suppl 77:8113-8119, 2000
34. Yosluji H, Kuriyama S, Ways DK, Yoshii J, Miyamoto Y, Kawata M, Ikenaka Y, Tsujinoue H, Nakatani T, Shibuya M, Fukui H: Protein kinase C lies on the signaling pathway for vascular endothelial growth factor-mediated tumor development and angiogenesis. Cancer Res 59:4413-4418, 1999
35. Takahashi T, Ueno H, Shibuya M: VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 18:2221-2230, 1999
36. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: ETDRS report no. 1. Arch Ophthalmol 103:1796-1806, 1985
37. Brown MM, Brown GC, Sharma S, Busbee B: Quality of life associated with visual loss: a time tradeoff utility analysis comparison with medical health states. Ophthalmology 110:1076-1081, 2003
38. Yuan SY, Ustinova EE, Wu MH, Tinsley JH, Xu W, Korompai FL, Taulman AC: Protein kinase C activation contributes to microvascular barrier dysfunction in the heart at early stages of diabetes. Circ Res 87:412-417, 2000
39. Saishin Y, Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA: Inhibition of protein kinase C decreases prostaglandin-induced breakdown of the blood-retinal barrier. J Cell Physiol 195:210-219, 2003
40. Chen ML, Pothoulakis C, LaMont JT: Protein kinase C signaling regulates ZO-1 translocation and increased paracellular flux of T84 colonocytes exposed to Clostridium difficile toxin A. J Biol Chem 277:4247-4254, 2002
41. Lacaz-Vieira F, Jaeger MM: Protein kinase inhibitors and the dynamics of tight junction opening and closing in A6 cell monolayers. J Membr Biol 184:185-196, 2001
42. Campochiaro PA: Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci 45:922-931, 2004
43. Yang CS, Cheng CY, Lee FL, Hsu WM, Liu JH: Quantitative assessment of retinal thickness in diabetic patients with and without clinically significant macular edema using optical coherence tomography. Acta Ophthalmol Scand 79:266-270, 2001
44. Early Treatment Diabetic Retinopathy Study Research Group: Focal photocoagulation treatment of diabetic macular edema: relationship of treatment effect to fluorescein angiographic and other retinal characteristics at baseline: ETDRS report no. 19. Arch Ophthalmol 113:1144-1155, 1995
45. Hee MR, Puliafito CA, Duker JS, Reichel E, Coker JG, Wilkins JR, Schuman JS, Swanson EA, Fujimoto JG: Topography of diabetic macular edema with optical coherence tomography. Ophthalmology 105:360-370, 1998
46. Jirousek MR, Gillig JR, Gonzalez CM, Heath WF, McDonald JH 3rd, Neel DA, Rito CJ, Singh U, Stramm LE, Melikian-Badalian A, Baevsky M, Ballas LM, Hall SE, Winneroski LL, Faul MM: (S)-13-[(dimethylamino)methyl]-10,11,14,15-tetrahydro4, 9:16, 21-dimetheno-1H, 13H-dibenzo[e,k]pyrrolo[3,4-h][1,4,13] oxadiazacyclohexadecene-1,3(2H)-d ione (LY333531) and related analogues: isozyme selective inhibitors of protein kinase C β. J Med Chem 39:2664-2671, 1996